Board of directors
Torsten Goesch, Chairman of the board
Dr. Torsten Goesch has been the director of Rosetta Capitala secondary life science investor since 2002. In this function he has been responsible for the management of several Rosetta Capital investments and as such has severed on several biotech company boards. Additionally, Dr. Goesch served as the General Manager for the German Speaking Countries at Biogen from 1997-1999, and before that he served as the Commercial Head of Merck KGaA’s worldwide generics drug business Merck Generics. He practiced as a doctor of internal medicine at the University Hospital Hamburg-Eppendorf from 1988-1990, focusing on nephrology, immunology and oncology. Dr. Goesch has a Master of Management from Northwestern University’s J.L. Kellogg Graduate School of Management, as well as a M.D. and Ph.D. from Heinrich Heine University Düsseldorf
Tom Pike holds a number of board positions within the life science industry in Norway and Sweden. Previous positions includes Partner in the venture capital fund NeoMed, Chairperson & CEO of Clavis Pharma ASA as well as Chairperson of the Association of the Pharmaceutical Industry in Norway. He has also worked at Hoffman-La Roche in Norway and Switzerland for 18 years, including 8 years as general manager in Norway. Mr Pike holds a B.Sc. Honours in Pharmacology.